Dianthus Therapeutics, Inc.
DNTH
$19.97
$0.020.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -38.95% | 16.59% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -38.95% | 16.59% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -38.95% | 16.59% | |||
| SG&A Expenses | 4.61% | 8.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.65% | 33.26% | |||
| Operating Income | -6.74% | -34.66% | |||
| Income Before Tax | -12.97% | -42.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.97% | -42.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.97% | -42.98% | |||
| EBIT | -6.74% | -34.66% | |||
| EBITDA | -6.74% | -34.69% | |||
| EPS Basic | -10.40% | -42.94% | |||
| Normalized Basic EPS | -8.45% | -44.70% | |||
| EPS Diluted | -10.40% | -42.94% | |||
| Normalized Diluted EPS | -8.45% | -44.70% | |||
| Average Basic Shares Outstanding | 2.33% | 0.03% | |||
| Average Diluted Shares Outstanding | 2.33% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||